Iterion Therapeutics Email Formats

Biotechnology Research • 7255 Helix Park Ave, Houston, United States • 11-20 Employees

Iterion Therapeutics Email Formats

Iterion Therapeutics uses 1 email format. The most common is {first name} (e.g., john@iteriontx.com), used 100% of the time.

Format	Example	Percentage
{first name}	john@iteriontx.com	100%

Key Contacts at Iterion Therapeutics

Gowri Sukumar

Senior Director Cmc And Regulatory Affairs

Prashi Jain

Director, Drug Discovery

Aundrietta Duncan

Sr. Director, Research And Non-Clinical Development

Company overview

Headquarters	7255 Helix Park Ave, Houston, Texas 77030, US
Phone number	+13175179500
Website	iteriontherapeutics.com
NAICS	541714
SIC	873
Founded	2015
Employees	11-20
Socials

About Iterion Therapeutics

Iterion Therapeutics is a clinical-stage biotechnology company developing novel small-molecule therapies that target the Wnt/β-catenin signaling pathway—one of the most validated, yet historically “undruggable,” oncogenic drivers. Our lead asset, Tegavivint, is a first-in-class inhibitor of TBL1 (Transducin β-like protein 1), a critical transcriptional co-activator of Wnt/β-catenin. Tegavivint treatment results in degradation of nuclear β-catenin and inhibition of Wnt-activated oncogenic transcription, offering a differentiated safety and efficacy profile versus prior approaches. Tegavivint has demonstrated encouraging anti-tumor activity and durable disease control in clinical studies, including patients with hepatocellular carcinoma (HCC) and desmoid tumors. Iterion is currently advancing Tegavivint in a Phase 2 clinical program in HCC and exploring expansion opportunities in other Wnt-driven cancers with high unmet need. Supported by leading investors and strategic partners, Iterion’s mission is to unlock the therapeutic potential of Wnt/β-catenin inhibition to deliver first-in-class targeted therapies for patients with aggressive cancers.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Senior

C-Suite

Director

Employees by Department

Iterion Therapeutics has 7 employees across 7 departments.

Departments

Number of employees

Funding Data

Explore Iterion Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2021-03-16	5	$17,000,000

Funding Insights

$17,000,000

Total funding amount

$17,000,000

Most recent funding amount

Number of funding rounds

Iterion Therapeutics Tech Stack

Discover the technologies and tools that power Iterion Therapeutics's digital infrastructure, from frameworks to analytics platforms.

reCAPTCHA

Security

WP Fastest Cache

Performance

Astra

WordPress themes

Slick

JavaScript libraries

Spectra

WordPress plugins

jQuery Migrate

JavaScript libraries

Apache HTTP Server

Web servers

jQuery

JavaScript libraries

PHP

Programming languages

WordPress

Blogs

Gutenberg

Editors

Yoast SEO

SEO

Frequently asked questions

Iterion Therapeutics is located in 7255 Helix Park Ave, Houston, US.

You can reach Iterion Therapeutics at +13175179500.

Iterion Therapeutics was founded in 2015, making it 11 years old. The company has established itself as a significant player in its industry over this time.

Iterion Therapeutics has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

Iterion Therapeutics has raised a total of $17,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at Iterion Therapeutics

Gowri Sukumar

Senior Director Cmc And Regulatory Affairs

Prashi Jain

Director, Drug Discovery

Aundrietta Duncan

Sr. Director, Research And Non-Clinical Development

4.8

40,000 users